drugset / Trial / NCT03709914

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

NCT03709914

Phase 1 Unknown 21 enrolled Nabriva Therapeutics AG
Non-randomizedSequentialOpen-labelBasic science

Summary

Phase 1 study, a single dose of ZTI-01 given to pediatric subjects (under 12 years of age) who require antibiotic therapy to see what the body does to the drug (pharmacokinetics) and to compare if these effects are similar to those observed in adults at a 6g ZTI-01 dose. Study will help establish pediatric dosing in younger children by age cohort. This is a multiple-center, open-label, PK study of ZTI-01 (fosfomycin for injection) single dose scaled by allometric weight-modeling from an adult ZTI-01 dose of 6 grams. Eligible subjects must be receiving standard of care antibiotics for proven or suspected bacterial infection or for peri-operative prophylaxis surgery (in or out of hospital).

Timeline

Start
2018-05-24
Primary completion
2025-12-31
Completion
2026-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosfomycin Small molecule 75 mg/kg Intravenous
Subject Fosfomycin Small molecule 100 mg/kg Intravenous